Why the study?
Drug selection criteria and evaluation methods related to the anti-TNF pleiotropic activity of antiplatelet drugs remain limited.
Does cilostazol reduce TNF-driven inflammatory responses more effectively than clopidogrel or sarpogrelate in a mouse model?
Population
TNF-induced inflammatory mouse model and MOVAS-1 aortic vascular smooth muscle cell line
Comparison
Clopidogrel vs sarpogrelate vs cilostazol
Design
Preclinical animal and cell culture comparative study
Authors
Loading...
Cilostazol may attenuate TNF-driven inflammation more than comparators in mice; leaves open translation to human cardiovascular disease.
Does cilostazol reduce TNF-driven inflammatory responses more effectively than clopidogrel or sarpogrelate in a mouse model?
Cilostazol demonstrates superior anti-inflammatory effects compared to clopidogrel and sarpogrelate in a TNF-driven mouse model, suggesting potential benefits for TNF-mediated inflammatory disorders.
Lee et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: